Boston Advisors’s Kyntra Bio KYNB Stock Holding History

Boston Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.17M	Buy	1,266 +481	+61%	+$528K	0.06%	359
2019 Q2	$887K	Sell	785 -3	-0.4%	-$3.28K	0.05%	386
2019 Q1	$1.07M	Sell	788 -2	-0.3%	-$2.71K	0.05%	330
2018 Q4	$914K	Buy	790 +615	+351%	+$691K	0.05%	334
2018 Q3	$266K	Sell	175 -448	-72%	-$690K	0.01%	584
2018 Q2	$975K	Buy	623 +81	+15%	+$106K	0.02%	378
2018 Q1	$626K	Buy	542 +40	+8%	+$52.7K	0.02%	455
2017 Q4	$595K	Sell	502 -7,543	-94%	-$9.46M	0.01%	469
2017 Q3	$10.8M	Buy	8,045 +1,045	+15%	+$1.1M	0.25%	120
2017 Q2	$5.65M	Buy	+7,000	New	+$4.88M	0.13%	196
2016 Q3	–	Sell	-789	Closed	-$324K	–	685
2016 Q2	$324K	Buy	789 +209	+36%	+$95.7K	0.01%	586
2016 Q1	$309K	Buy	580 +4	+0.7%	+$1.99K	0.01%	574
2015 Q4	$439K	Buy	+576	New	+$382K	0.01%	488

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Boston Advisors's KYNB Position: Q3 2019 in Review

Boston Advisors increased its Kyntra Bio (KYNB) stake by 61% in Q3 2019, buying an estimated $528K and bringing the position to 1,266 shares worth $1.17M. The position accounts for 0.06% of the portfolio, ranked #359.

Boston Advisors first reported a position in KYNB in Q4 2015 and has held it in 13 quarters since. The position peaked at $10.8M in Q3 2017. 210 funds tracked by Wall St. Rank hold KYNB as of Q3 2019.

Boston Advisors held 1,266 shares of Kyntra Bio worth $1.17M as of Q3 2019.
Boston Advisors bought 481 Kyntra Bio shares in Q3 2019, an estimated $528K.
Kyntra Bio made up 0.06% of Boston Advisors's portfolio in Q3 2019, its #359 holding.
Boston Advisors first reported a position in Kyntra Bio in Q4 2015 and has held it in 13 quarters since.
Boston Advisors's Kyntra Bio position peaked at $10.8M in Q3 2017.
210 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.